|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||184.17 - 187.45|
|52 Week Range||150.38 - 191.10|
|PE Ratio (TTM)||16.76|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||5.28 (2.85%)|
|1y Target Est||192.14|
Amgen Inc (NASDAQ:AMGN), a large-cap worth $134.32B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenue andRead More...
Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. The Marijuana Index is a series of equally weighted stock indexes that track the leading cannabis stocks in the U.S. and Canada. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a market cap of $3.34 billion, produces a multiple sclerosis treatment using nabiximols, an herbal preparation containing a defined quantity of specific cannabinoids with potential analgesic activity.
Announcement: Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law. Global Credit Research- 09 Jan 2018. New York, January 09, 2018-- US pharmaceutical companies' cash holdings ...
PRESS RELEASE : 9 January 2018, 07:01 CET Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound Mechelen, Belgium, 9 January 2018 - Biocartis Group NV (the `Company` ...
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture.